Related Experiment Video
Updated: Jan 8, 2026

07:31
A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
Published on: February 13, 2020
7.3K
Technology and Dementia Preconference
Amy Hwang1, Thomas Tannou2, Jarshini Nanthakumar3
1Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Montreal, QC, Canada.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 23, 2025
Summary
Artificial intelligence in aging and dementia care (AI AgeTech) requires a humanistic approach. This technology involves semi-autonomous actors that reshape care relationships and practices within dementia care ecosystems.
Area of Science:
- Geriatrics
- Artificial Intelligence Ethics
- Social Robotics
Background:
- Digitization necessitates technology engagement for health, care access, and social participation.
- AI AgeTech (smart homes, robots, wheelchairs) supports persons with dementia and care partners.
- Existing AI ethics discussions address individual and societal issues, but not the relational dynamics of dementia care.
Purpose of the Study:
- To explore how AI AgeTech shapes and is shaped by evolving dementia care ecosystems.
- To develop a guiding model for designing AI AgeTech for dementia care.
Main Methods:
- Co-creation workshops with diverse stakeholders (researchers, persons with dementia, care partners, entrepreneurs).
- Utilized visual experience probes (personas, care maps, scenarios, videos) to stimulate discussion.
- Synthesized a preliminary guiding model for AI AgeTech innovation.
Main Results:
- A humanistic, relational model for designing AI AgeTech was developed.
- AI AgeTech are viewed as semi-autonomous care actors, not just tools.
- These systems are likely to reshape care relationships and practices within dementia care ecosystems.
Conclusions:
- Designing AI for dementia care necessitates a humanistic, relational understanding beyond current AI ethics.
- The developed model offers actionable guidance for innovators.
- This approach is crucial for enhancing dementia care in an AI-influenced future.
Related Concept Videos
Dementia
482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

